Molecular therapy for Inflammatory Bowel disease (IBD): p63 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in inflammatory bowel disease (IBD) via down regulation of its target gene, 10/February/2015, 23.22

AntagomiR-based therapy for T2DM: MiRNA-4500 promotes glucose intolerance and insulin resistance via down regulation of its target gene, 10/February/2015, 23.16
February 10, 2015
Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015, 23.25
February 10, 2015
Show all

A study from Department of Medicine, University of Chicago, Chicago, Illinois, USA shows that “Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation.” This study was published in the February 2, 2014 issue of J Clin Invest by Prof. Eugene B. Chang & Dr. Xiaorong Zhu.

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for Inflammatory Bowel disease (IBD):  p63 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in  inflammatory bowel disease (IBD) via down regulation of its target geneThus, this study suggests that pharmacological formulations encompassing “p63 activators” may be used in the treatment of Inflammatory Bowel disease (IBD).

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500*

Undisclosed information: How p63 decreases tissue injury in  inflammatory bowel disease (IBD) 

To citeBoominathan, Molecular therapy for Inflammatory Bowel disease (IBD):  p63 preserves the functions of Beclin 1 and ATG5 and decreases tissue injury in  inflammatory bowel disease (IBD) via down regulation of its target gene, 10/February/2015, 23.22, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.